DOCSLIB.ORG

Neuromuscular Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuromuscular Diseases Neuromuscular Diseases Muscular Dystrophy Association MUSCULAR DYSTROPHIES www.mda.org Cure CMD (Congenital Muscular Dystrophy) Voluntary health agency that fosters neuromuscular disease http://curecmd.org/ research and provides patient care funded almost entirely Nonprofit group whose mission is to bring research, treat- by individual private contributors. MDA addresses the mus- ments and, in the future, a cure for the congenital mus- cular dystrophies, spinal muscular atrophy, ALS, Charcot- cular dystrophies. Works globally with dedicated parent, Marie-Tooth disease, myasthenia gravis, Friedreich’s ataxia, government, and research advocates funds high potential metabolic diseases of muscle, and inflammatory diseases of research and clinical trials, with success being determined by muscle, for a total of more than 40 neuromuscular diseases. clinical applications that improve the lives of those afflicted with CMDs. AMYOTROPHIC LATERAL SCLEROSIS ALS Therapy Development Institute Fibromuscular Dysplasia Society of America www.als.net (FMDSA) Nonprofit biotechnology company dedicated to discover- www.fmdsa.com ing and developing treatments for ALS. The organization A public health charity working toward better diagnosis and focuses on a concentrated drug discovery program for ALS treatment of fibromuscular dysplasia by building awareness, and collaborates with companies and academic researchers funding research, providing patient support, and educating to perform advanced investigations. patients and the healthcare community. The ALS Association FSH Society (Facioscapulohumeral Dystrophy) www.alsa.org www.fshsociety.org Nonprofit voluntary health organization dedicated solely Helps patients and families through education and outreach to the fight against amyotrophic lateral sclerosis. Funds via a newsletter, website, conferences and social media funds research and sponsors advocacy programs, a network of scientific research leading to treatments, guided by a world- chapters, and certified centers and clinics located nation- class Scientific Advisory Board and advocates for increased wide. government and industry funding for research and to encourage drug trials. Les Turner ALS Foundation www.lesturnerals.org Jain Foundation Advances scientific research into the causes, treatments and www.jain-foundation.org prevention of ALS, provides people living with ALS, their Seeks to expedite development of a cure or therapy for families and caregivers exceptional clinical care and support Limb-girdle muscular dystrophy type 2B (LGMD2B) and services, and increases awareness and education of ALS. Miyoshi Myopathy. Maintains a patient registry, funds and monitors research and progress, provides financial support Project ALS to accelerate clinical trials, and encourages scientific collabo- www.projectals.org ration. Nonprofit organization that raises awareness and funds toward treatments and a cure for amyotrophic lateral scle- Muscular Dystrophy Association rosis. www.mda.org Voluntary health agency that fosters neuromuscular disease PRIZE4LIFE research and provides patient care funded almost entirely www.prize4life.org by individual private contributors. MDA addresses the mus- Nonprofit organization dedicated to the discovery of treat- cular dystrophies, spinal muscular atrophy, ALS, Charcot- ments and a cure for ALS. Marie-Tooth disease, myasthenia gravis, Friedreich’s ataxia, metabolic diseases of muscle, and inflammatory diseases of muscle, for a total of more than 40 neuromuscular diseases. Practical Neurology ® Neuromuscular Diseases Muscular Dystrophy Charcot-Marie-Tooth Association (CMTA) www.curecalpain3.org/ www.charcot-marie-tooth.org Coalition to Cure Calpain 3 (C3) Coalition to Cure Calpain Provides education and support to persons with Charcot- 3 provides support for promising research into finding treat- Marie-Tooth disorders, their families, and the health profes- ments or a cure for limb-girdle muscular dystrophy, type sionals who treat them. 2A/Calpainopathy (LGMD2A). Hereditary Neuropathy Foundation The Myositis Association www.hnf-cure.org www.myositis.org Nonprofit organization that raises awareness, funds innova- Works to improve the lives of those affected by inflam- tive research, and offers medical information and emotional matory myopathies. Seeks out persons with inflammatory support for those with Charcot-Marie-Tooth disorder and myopathies, provides a support network, acts as a resource their families and caregivers. for patients and the medical community, advocates for patients, and promotes research into the causes and treat- The Foundation for Peripheral Neuropathy ment of these disorders. www.foundationforpn.org Nonprofit organization whose mission is to dramatically Myotonic Dystrophy Foundation improve the lives of people living with peripheral neuropa- www.myotonic.org thy. Enhances the quality of life of people living with myotonic dystrophy and advances research focused on treatments PARALYSIS and a cure. The world’s largest patient organization focused Christopher and Dana Reeve Foundation solely on myotonic dystrophy. www.christopherreeve.org The Christopher & Dana Reeve Foundation is dedicated to Parent Project Muscular Dystrophy curing spinal cord injury by funding innovative research and www.endduchenne.org improving the quality of life for people living with paralysis Dedicated to ending Duchenne muscular dystrophy through through grants, information and advocacy. accelerated research and advocacy. Demands optimal care for all young men and educates the global community. Miami Project to Cure Paralysis www.themiamiproject.org MYASTHENIA GRAVIS Supports research and related programs in the area of spinal yasthenia Gravis Foundation of America, Inc cord injury. www.myasthenia.org Works to facilitate the timely diagnosis and optimal care of Spastic Paraplegia Foundation, Inc. individuals affected by myasthenia gravis and closely related www.sp-foundation.org disorders and to improve their lives through programs of Volunteer nonprofit organization dedicated to finding cures patient services, public information, medical research, pro- for hereditary spastic paraparesis and primary lateral sclero- fessional education, advocacy, and patient care. sis. See also Genetic Alliance, page 41, and National Ataxia Foundation, page 8. NEUROPATHIES American Diabetes Association The Spinal Cord Society www.diabetes.org www.scsus.org/ Nonprofit health organization providing diabetes research, International advocacy organization that supports research, advocacy services, and information, including the complica- publishes a newsletter, and sponsors an international net- tions of diabetes, such as diabetic neuropathy. work of chapters. Practical Neurology ® Neuromuscular Diseases SPASMODIC DYSPHONIA Fight SMA National Spasmodic Dysphonia Association www.fightsma.org www.dysphonia.org National nonprofit organization committed to accelerating Works to advance medical research into the causes of and a cure for spinal muscular atrophy. treatments for spasmodic dysphonia, promotes physician and public awareness of the disorder, and sponsors support Kennedy’s Disease Association groups for patients and their families. www.kennedysdisease.org Nonprofit resource that offers support and information SPINAL MUSCLE ATROPHIES about spinal bulbar muscular atrophy, or Kennedy’s disease. Cure SMA Works to increase awareness and to raise funds in support www.curesma.org of research. Sponsors support groups. Provide funding for SMA research through our comprehen- sive research model leading providers of family support and Spinal Muscular Atrophy Foundation patient services. www.smafoundation.org Nonprofit foundation dedicated to accelerating the devel- opment of a treatment or cure for SMA. Practical Neurology ®.
Load more

Recommended publications
  • 46 L Nursing2015 L Volume 45, Number 10 46 L
    46 l Nursing2015 l Volume 45, Number 10 www.Nursing2015.com Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. 2.0 ANCC ALCONTACT HOURSS Amyotrophic lateral sclerosis: What nurses need to know By Tamara L. Bellomo, MSN, RN-BC, and Lucille Cichminski, MSN, RN A MOTHER OF THREE teenage children, Mrs. is one of the most common neuromuscular dis- S, 49, presented to her healthcare provider eases in the world. This rapidly progressive, fatal with bilateral leg twitching and weakness, dif- neuromuscular disease involves the degeneration ficulty swallowing, and fatigue that’s worsened and death of the upper and lower motor neu- over the past few weeks. While she was on her rons.1 This article discusses the diagnosis and daily morning walk, she tripped and fell. She treatment of ALS and how nurses can help their experienced a small laceration to her leg, patients deal with the difficult diagnosis and find prompting her visit to the healthcare facility. the resources they and their families need. Her husband said that she’d had periods of slurred speech over the past few months as Who’s affected? well. She was alert and oriented, and her vital An estimated 20,000 to 30,000 Americans are signs were all within normal limits. living with ALS, and about 5,000 new cases After an exam, her healthcare provider are diagnosed each year in the United States.2 referred her to a neurologist who ordered This disease affects people of all ethnic, socio- magnetic resonance imaging (MRI), an electro- economic, and racial backgrounds.2,3 ALS most HOTOTAKE / P myogram, and a full bloodwork panel.
    [Show full text]
  • FUNDELA Boletín Científico 45
    ABRIL 2013 Fundación Española para el Fomento de la Investigación de la Esclerosis Lateral Amiotrófica FUNDELA Boletín Científico 45 El boletín de FUNDELA publica resúmenes y artículos científicos referentes a los últimos avances de la investigación, tratamientos sintomáticos y cuidados al paciente con ELA. Se envía periódicamente a más de 400 suscriptores, entre los que se encuentran profesionales de la salud, pacientes y familiares de España y Latinoamérica. Todos los boletines pueden descargarse en nuestra web www.fundela.es FUNDELA no asume responsabilidades por la información que contiene este boletín. Necesitamos ayuda económica para continuar en los proyectos que indicamos a continuación •PROYECTOS PILOTO DE DETERMINACION DE DIFERENTES POSIBLES BIOMARCADORES EN PLASMA Y CELULAS MONONUCLEARES DE SANGRE PERIFERICA EN PACIENTES CON ELA •PUESTA A PUNTO DE UN ALGORITMO MOLECULAR DIAGNOSTICO EN PACIENTES CON ELA Y DEGENERACION LOBULAR FRONTOTEMPORAL •REHABILITACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA: TERAPIA OCUPACIONAL Y LOGOPEDIA •BOLETIN CIENTIFICO Actualmente contamos con subvenciones de SEALED AIR BUÑOL, Fundación MUPITI y FRANHUR, La Caixa y aportaciones particulares de pacientes y familiares que sufren la ELA. Su donativo le dará derecho a practicar una deducción en la cuota del impuesto sobre la renta. La deducción será del 25% como persona física y del 35% como empresa. Para realizar donaciones económicas pedimos suscribirse en nuestra página web: http://www.fundela.es/captaBanco.php Colaboradores voluntarios de este número: Dr. Alberto García Redondo (Bioquímico, Unidad Hospital 12 de octubre) de ELA – Hospital 12 de octubre) Dra. María Teresa Solas (Bióloga, Universidad Dra. Elena Rodríguez García (Bioquímica – Complutense) Voluntaria FUNDELA) Dra. Teresa Salas (Psicóloga, Unidad de ELA - Dr.
    [Show full text]
  • BOOK of ABSTRACTS OXFORD ENCALS Meeting 2018
    2018 MEETING 20-22 JUNE 2018 BOOK OF ABSTRACTS OXFORD ENCALS Meeting 2018 Acknowledgements ENCALS would like to thank the following sponsors for their generous support of this year’s meeting. Gold Sponsor Silver Sponsors Bronze Sponsors 2 ENCALS Meeting 2018 Poster Session 1: Wednesday 20th June, 18:00 - 19:30 Entrance Hall: A01 Hot-spot KIF5A mutations cause familial ALS David Brenner* (1), Rüstem Yilmaz (1), Kathrin Müller (1), Torsten Grehl (2), Susanne Petri (3), Thomas Meyer (4), Julian Grosskreutz (5), Patrick Weydt (1, 6), Wolfgang Ruf (1), Christoph Neuwirth (7), Markus Weber (7), Susana Pinto (8, 9), Kristl G. Claeys (10, 11, 12), Berthold Schrank (13), Berit Jordan (14), Antje Knehr (1), Kornelia Günther (1), Annemarie Hübers (1), Daniel Zeller (15), The German ALS network MND-NET, Christian Kubisch (16, 17), Sibylle Jablonka (18), Michael Sendtner (18), Thomas Klopstock (19), Mamede de Carvalho (8, 20), Anne Sperfeld (14), Guntram Borck (16), Alexander E. Volk (16, 17), Johannes Dorst (1), Joachim Weis (10), Markus Otto (1), Joachim Schuster (1), Kelly del Tredici (1), Heiko Braak (1), Karin M. Danzer (1), Axel Freischmidt (1), Thomas Meitinger (21), Tim M. Strom (21), Albert C. Ludolph (1), Peter M. Andersen (1, 9), and Jochen H. Weishaupt (1) Heterozygous missense mutations in the N-terminal motor or coiled-coil domains of the kinesin family member 5A (KIF5A) gene cause monogenic spastic paraplegia (HSP10) and Charcot-Marie-Tooth disease type 2 (CMT2). Moreover, heterozygous de novo frame-shift mutations in the C-terminal domain of KIF5A are associated with neonatal intractable myoclonus, a neurodevelopmental syndrome.
    [Show full text]
  • Drug Development for Amyotrophic Lateral Sclerosis Guidance for Industry
    Drug Development for Amyotrophic Lateral Sclerosis Guidance for Industry August 2017 Contents I. INTRODUCTION ................................................................................................................ 1 II. BACKGROUND ................................................................................................................... 2 III. BENEFIT RISK...................................................................................................................... 5 A. General comments .................................................................................................................. 5 B. Evidence of patient and caregiver preferences ....................................................................... 5 C. Implications of patient risk/benefit preferences in ALS ......................................................... 7 1. Alternative endpoints........................................................................................................... 7 2. Placebo control arm ............................................................................................................. 8 3. Threshold for statistical significance ................................................................................... 9 4. Method of delivery ............................................................................................................ 10 5. Role of expanded access and accelerated approval ........................................................... 11 6. Patient protection and need for informed
    [Show full text]
  • 2020-ALS-Mission-Toolkit Web.Pdf
    OUR MISSION OUR MISSION TABLE OF CONTENTS OUR MISSION Our Case for Support . iv Annual Impact . v Our Vision and Mission . vi CHAPTER 1: RESEARCH The ALS Association Research Program The ALS Association Research Program . 1–1 Research . 1–5 Our Strategic Initiatives . 1–5 Infographics Current Projects . 1–13 Accelerating the Search for a Cure . 1–14 Research By the Numbers . 1–15 Research Strategy . 1–16 Funded Research . 1–17 Scientific Focus Areas . 1–18 Advances in ALS Research . 1–20 Research Initiatives The ALS Association’s ALS Roundtable Program . 1–22 ALS Voice of The Patient Report . 1–24 ALS Focus Survey Program . 1–26 Research Staff . 1–28 CHAPTER 2: CARE SERVICES How We Work Summary . 2–1 How We Work . 2–2 Chapter Membership . 2–4 ii How We Support Clinical Care Supporting Clinical Care . 2–11 Certified Centers . 2–14 Where We Support Care . 2–15 Impact & Resources Care Services Impact . 2–20 Filling the Gap . 2–21 Education — Living with ALS: General Scope . 2–22 Education — Living with ALS: Medical Resources . 2–24 Assistive Technology — Assistive Technology in the ALS Space . 2–26 Children’s Programs and Resources . 2–28 The Jane Calmes ALS Scholarship Fund . 2–32 ALS Association Care Connection . 2–33 Care Services Staff . 2–34 CHAPTER 3: ADVOCACY Introduction To ALS Advocacy Introduction . 3–1 History of ALS Advocacy . 3–2 History of ALS Advocacy: Timeline . 3–3 Advocacy Action Advocacy Guiding Principles . 3–5 How We Advocate . 3–6 Priorities, Impact, and Coalitions ALS Guidance . 3–10 Advocacy Impact .
    [Show full text]
  • A Er the Wildly Successful Ice Bucket Challenge
    RESEARCH FEBRUARY/MARCH 2015 BY GINA SHAW Azer the Wildly Successful Ice Bucket Challenge ~e Ice Bucket Challenge raised big bucks on social media. Now, the ALS Association tells us where that cold, hard cash is going. As snowstorms and icy winds batter much of the country, it's hard to imagine willingly pouring a bucket of ice water over your head for any reason. But last August—when temperatures were much more forgiving—that's exactly what about 3 million people did. In an astonishing example of the power of social media, a July 31 dare from former Boston College baseball player Pete Frates, who was diagnosed with amyotrophic lateral sclerosis (ALS) in 2012, quickly went viral. The dare? Dump ice water on your head within 24 hours of being challenged or donate $100 (or whatever amount you could afford) to the ALS Association or another organization supporting ALS research. Pretty soon, the Ice Bucket Challenge meant dumping ice on your head and donating money, and everyone from your neighbor's preschooler to Bill Gates (with a custom-built ice douser), Oprah Winfrey, Jon Bon Jovi, and entire casts of Broadway shows were doing it—and posting their videos online. Even 86-year-old Ethel Kennedy took the challenge. (President Obama donated but declined the ice; actor Patrick Stewart posted a video of himself writing a check.) In La Jolla, CA, prominent ALS researcher Don Cleveland, PhD, who pioneered a novel therapy that turns off the defective genes that contribute to neurodegenerative diseases, watched the online commotion with skepticism.
    [Show full text]
  • Technologies for Improving the Lives of People With
    Technologies for improving the UW CSE MSR Summer lives of people with ALS Institute 2016 Rico Malvar Expanding Chief Scientist and Distinguished Engineer Accessibility Research What is ALS (Lou Gehrig’s Disease) • ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. A-myo-trophic comes from the Greek language. "A" means no. "Myo" refers to muscle, and "Trophic" means nourishment – "No muscle nourishment." When a muscle has no nourishment, it "atrophies" or wastes away. Lateral identifies the areas in a person's spinal cord where portions of the nerve cells that signal and control the muscles are located. As this area degenerates it leads to scarring or hardening ("sclerosis") in the region. • Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their demise. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, people may lose the ability to speak, eat, move and breathe. The motor nerves that are affected when you have ALS are the motor neurons that provide voluntary movements and muscle control. Examples of voluntary movements are making the effort to reach for a smart phone or step off a curb. These actions are controlled by the muscles in the arms and legs. Source: “What is ALS”, ALS Association Ten Things about ALS 1. Every 90 minutes someone in the US is diagnosed with ALS.
    [Show full text]
  • 24Th Annual Meeting Sunday and Monday, 4-‐5 December 2016
    24th Annual Meeting Sunday and Monday, 4-5 December 2016 Liffey Hall 2, Convention Centre Dublin AGENDA SUNDAY, 4 DECEMBER 2016 08:45 1 Welcome & Introduction (30 min) 09:15 Annual General Meeting (45 min) 10:00 2 Opening Remarks from the General Manager (15 min) 10:15 Morning Refreshments (30 min) 10:45 3 Welcoming Our NeW Members (15 min) 11:00 Programming for PALS/CALS (60 min) 4 Beyond Awareness Gaps Hiroki Okabe, Japan ALS Association 5 The Cost of Achieving Your Goals: Assistive Technology Program in Israel Efrat Carmi, IsrALS 6 A Comprehensive Information and Education Resource for People with MND, their Carers, Health and Community Care Providers Gina Svolos, MND Australia 7 New Challenges to Our Association Alessandra Dorca, ALS Pro-Cura Association 12:00 Lunch (60 min) 13:00 Programming for PALS/CALS Continued (30 min) 8 ACELA: A Vision of Hope Rocio Reyes, ACELA, Colombia 9 Life Is Now Gudjon Sigurdsson, MND Iceland 13:30 Partnerships and Collaborations (90 min) 10 A Phased Shift in MND Care in Scotland Craig Stockton, MND Scotland 11 Victories and Partnerships Tatiana Mesquita e Silva, ABrELA 12 Local Fundraising for Project MinE Gorrit-Jan Blonk, ALS Netherlands 13 Using the MND Association’s Experience to Promote Optimal Care and Support in Russia Anna Kassianova, Martha-Mary Medical Centre “Miloserdie” 14 The South African MND Caregiving Experience: Lessons Learned from a Cross-Country Collaboration Melinda Kavanaugh, University of Wisconsin-MilWaukee 15 First Ever ALS Student Exchange Jodi O’Donnell, Hope Loves Company
    [Show full text]
  • Real Or Perceived Amyotrophic Lateral Sclerosis (ALS) Objectives
    10/11/2019 Nursing Care and Considerations of Patients with Amyotrophic Lateral Sclerosis (ALS) 40th Annual Neurorehabilitation Conference on Traumatic Brain Injury, Stroke and Other Neurological Disorders Saturday & Sunday, November 16 & 17, 2019 Hyatt Regency Cambridge 575 Memorial Drive • Cambridge, MA encompasshealth.com/braintreerehab Vincent M. Vacca, Jr., MSN, RN 1 Conflicts of interest – Real or Perceived • NONE 2 Amyotrophic Lateral Sclerosis (ALS) Objectives: 1. Following this presentation the learner will be able to list three signs and symptoms of motor neuron dysfunction found in ALS. 2. Following this presentation the learner will be able to explain three diagnostic tests utilized to establish diagnosis of ALS. 3. Following this presentation the learner will be able to describe three essential nursing interventions guided by best practices and care of patients with ALS. 3 1 10/11/2019 The median age of ALS onset is 55 years • ALS affects about one in every 300 people. • About 30,000 currently with 5,000 new cases per year. • ALS is sporadic in 90% of cases and show familial inheritance in the remaining 10%. • Estimates of the median survival of people with ALS vary between 27 and 64 months. • Death from ALS is primarily pulmonary. 4 ALS is the most frequent motor neuron disorder in adults • Due to degeneration of upper and lower motor neurons in spinal and bulbar myotomes. • Most studies show male predominance with a gender ratio of 3:2, but gender differences are age related. • Age of onset tends to be later in females than in males (68.4 years vs. 61.5 years).
    [Show full text]
  • How Common Are ALS Plateaus and Reversals?
    How common are ALS plateaus and reversals? Richard S. Bedlack, MD, ABSTRACT PhD Objective: To determine the frequency of amyotrophic lateral sclerosis (ALS) plateaus and rever- Timothy Vaughan, PhD sals in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. Paul Wicks, PhD Methods: We analyzed Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) and Jamie Heywood ALSFRS–revised (ALSFRS-R) data from PRO-ACT participants. The frequencies of participants Ervin Sinani experiencing plateaus (periods where scores did not change) were calculated over 6-, 12-, and Roger Selsov 18-month epochs. The percentage of participants ever experiencing reversals (periods where Eric A. Macklin, PhD scores improved) of different lengths were also calculated and plotted. David Schoenfeld, PhD Merit Cudkowicz, MD Results: Over 6 months, 25% of 3,132 participants did not decline. Over 12 months, 16% of Alex Sherman 2,105 participants did not decline. Over 18 months, 7% of 1,218 participants did not decline. Small ALS reversals were also common, especially over shorter follow-up intervals; 14% of 1,343 participants had a 180-day interval where their ALSFRS-R slope was greater than zero. Correspondence to Fewer than 1% of participants ever experienced improvements of 4 or more ALSFRS-R points Dr. Bedlack: lasting at least 12 months. [email protected] Conclusion: ALS plateaus and small reversals are common, especially over brief intervals. In light of these data, stable disease, especially for a short period of time, should not be interpreted as an ALS treatment effect. Large sustained ALS reversals, on the other hand, are rare, potentially important, and warrant further study.
    [Show full text]
  • Amyotrophic Lateral Sclerosis (ALS)?
    Amyotrophic Lateral Sclerosis U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Amyotrophic Lateral Sclerosis What is amyotrophic lateral sclerosis (ALS)? myotrophic lateral sclerosis (ALS) is a A rare neurological disease that affects nerve cells (neurons) in the brain and spinal cord that control voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, breathing and talking. The disease is progressive, meaning the symptoms get worse over time. Currently, there is no cure for ALS and no effective treatment to halt, or reverse, the progression of the disease. ALS belongs to a wider group of disorders known as motor neuron diseases, which are caused by gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. These motor neurons initiate and provide vital communication links between the brain and the voluntary muscles. Messages from motor neurons in the brain (called upper motor neurons) are transmitted to motor neurons in the spinal cord and to motor nuclei of brain (called lower motor neurons) and from the spinal cord and motor nuclei of brain to a particular muscle or muscles. 1 In ALS, both the upper motor neurons and the lower motor neurons degenerate or die, and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. Early symptoms of ALS usually include muscle weakness or stiffness. Gradually all muscles under voluntary control are affected, and individuals lose their strength and the ability to speak, eat, move, and even breathe.
    [Show full text]
  • Guidance for Industry Drug Development for Amyotrophic Lateral Sclerosis
    Guidance for Industry Drug Development for Amyotrophic Lateral Sclerosis ALS Guidance Participants The following individuals were leading participants in the patient-centered, community-led ALS Guidance initiative. Steering Committee: • Barb Newhouse, Steering Committee Chair; President and CEO, The ALS Association • Lucie Bruijn, Steering Committee Vice Chair; Chief Scientist, The ALS Association • Hiroshi Mitsumoto, Steering Committee Vice Chair; Columbia MDA/ALS Research Center • Rick Bedlack, chair, Public Policy working group; Duke University Medical Center • James Berry, chair, Biomarkers working group; Massachusetts General Hospital • Benjamin Brooks, chair, Benefit/Risk working group; Carolinas Health System • Merit Cudkowicz, co-chair, Clinical Trials and Outcome Measures working group; Massachusetts General Hospital • Valerie Cwik, Muscular Dystrophy Association, EVP and Chief Medical and Scientific Officer • Ted Harada, co-chair, Patient & Caregiver Advisory Committee; Person with ALS, ALS Association National Trustee • Don Johns, Steering Committee Member; Vice President, Head ALS Neuroscience Discovery & Development, Biogen • Catherine Lomen-Hoerth, chair, FTD/ALS working group; UCSF • Nicholas Maragakis, chair, Diagnosis working group; Johns Hopkins Hospital • Tim Miller, chair, Natural History working group; Washington University School of Medicine • Elizabeth Ottinger, Steering Committee Member; NIH/NCATS • Steve Perrin, Steering Committee Member; ALS Therapy Development Institute, Chief Scientific Officer • Jeremy Shefner,
    [Show full text]